多组学技术在代谢相关脂肪性肝病临床异质性研究中的应用OA

Metabolic associated fatty liver disease(MAFLD)is the most prevalent chronic liver disease worldwide and has become an important public health issue.MAFLD not only impairs liver function but is also closely associated with an increased risk of multi-system diseases,including cardiovascular disease,chronic kidney disease,and type 2 diabetes mellitus.However,current treatment for MAFLD still faces challenges such as a lack of effective drugs and significant limitations in drug efficacy.The core challenge lies in the high degree of clinical heterogeneity among MAFLD patients.This article systematically reviews the breakthrough research findings achieved by multi-omics technologies(including genome-wide association analysis,transcriptome sequencing,proteomics,and metabolomics)in deciphering the heterogeneity of MAFLD,and summarizes the MAFLD subtypes and their molecular mechanisms defined based on the above multi-omics characteristics,thereby providing a critical scientific basis for precision risk stratification and the development of personalized therapeutic targets for MAFLD patients.